Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 40Myelodysplastic Syndromes 8Leukemia, Biphenotypic, Acute 6Leukemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Leukemia, Myelomonocytic, Chronic 3Neoplasm, Residual 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid 2Blast Crisis 2Sarcoma, Myeloid 1Neoplasms by Histologic Type 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma 1Liver Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Hematologic Neoplasms 1Down Syndrome 1Congenital Abnormalities 1Carcinoma, Hepatocellular 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine 4Cyclophosphamide 4Cisplatin 4pembrolizumab 3atezolizumab 3Pemetrexed 3fludarabine phosphate 2entrectinib 2durvalumab 2cobimetinib 2capmatinib 2alectinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Paclitaxel 2Nivolumab 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2130-nm albumin-bound paclitaxel 2trametinib 1spartalizumab 1ruxolitinib 1repotrectinib 1pralsetinib 1ponatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Idarubicin × 1 year × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡